The Evolution of Asthma Management: A Comprehensive Analysis of GINA 2024 Guidelines, Endotype-Driven Diagnosis, and Targeted Biologic Intervention

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 3 | 02 | Page :
    By

    Kuldeep Kate,

  • Gopal Lohiya,

  • Kranti Satpute,

  • Prakash Honrao,

  • Aniket Salunke,

  • Yogesh Chavan,

  1. Research Scholar, Department of Pharmaceutical Quality Assurance, Dayanand Education Society’s, Dayanand College of Pharmacy, Latur, Maharashtra, India
  2. Associate Professor, Department of Pharmaceutical Quality Assurance, Dayanand Education Society’s, Dayanand College of Pharmacy, Latur, Maharashtra, India
  3. Principal, Department of Pharmaceutical Quality Assurance, Dayanand Education Society’s, Dayanand College of Pharmacy, Latur, Maharashtra, India
  4. Research Scholar, Department of Pharmaceutical Quality Assurance, Dayanand Education Society’s, Dayanand College of Pharmacy, Latur, Maharashtra, India
  5. Research Scholar, Department of Pharmaceutical Quality Assurance, Dayanand Education Society’s, Dayanand College of Pharmacy, Latur, Maharashtra, India
  6. Research Scholar, Department of Pharmaceutical Quality Assurance, Dayanand Education Society’s, Dayanand College of Pharmacy, Latur, Maharashtra, India

Abstract

Asthma remains a substantial global public health challenge, characterized by heterogeneous airway inflammation leading to variable airflow obstruction. Recent advances in personalized medicine and guideline revisions, notably the Global Initiative for Asthma (GINA) 2024 update, mandate a profound paradigm shift from reliance on short-acting beta2-agonists (SABA) to antiinflammatory reliever (AIR) strategies utilizing inhaled corticosteroid (ICS)-formoterol. This report provides an exhaustive analysis of current asthma epidemiology, molecular pathogenesis distinguishing between Type 2 (T2)-high and T2-low endotypes—and contemporary diagnostic standards. A detailed clinical case study of a 9-year-old boy with severe eosinophilic asthma is presented to demonstrate the transformative efficacy of targeted biological therapy (Mepolizumab) in achieving clinical and functional reversal following a severe infectious exacerbation. The synthesis underscores the necessity of meticulous phenotyping, adherence assessment, and comorbidity management as prerequisites for achieving disease control and optimizing resource allocation in advanced severe asthma care.

Keywords: Asthma, GINA 2024, Eosinophilic Asthma, Mepolizumab, Airway Remodelling, SARS-CoV-2, Biologics, Paediatric Asthma, Anti-inflammatory Reliever (AIR).

How to cite this article:
Kuldeep Kate, Gopal Lohiya, Kranti Satpute, Prakash Honrao, Aniket Salunke, Yogesh Chavan. The Evolution of Asthma Management: A Comprehensive Analysis of GINA 2024 Guidelines, Endotype-Driven Diagnosis, and Targeted Biologic Intervention. Recent Trends in Infectious Diseases. 2026; 03(02):-.
How to cite this URL:
Kuldeep Kate, Gopal Lohiya, Kranti Satpute, Prakash Honrao, Aniket Salunke, Yogesh Chavan. The Evolution of Asthma Management: A Comprehensive Analysis of GINA 2024 Guidelines, Endotype-Driven Diagnosis, and Targeted Biologic Intervention. Recent Trends in Infectious Diseases. 2026; 03(02):-. Available from: https://journals.stmjournals.com/rtid/article=2026/view=247859


References

1. Global Initiative for Asthma. GINA 2024 guidelines emphasize the importance of switching from single SABA use to early ICS-formoterol (or ICS plus SABA) use for the relievermedication [Internet]. 2024. Available from:https://pmc.ncbi.nlm.nih.gov/articles/PMC11482852/
2. Missouri State Medical Association. The 2024 GINA strategy divides treatment into two Tracks: Track 1 (preferred Track), the reliever is as-needed combination low doseICSformoterol; Track 2 uses SABA as the reliever along with a separate ICS inhaler[Internet]. 2024. Available from: https://pubmed.ncbi.nlm.nih.gov/39421468/
3. GINAAsthma.org. Global Strategy for Asthma Management and Prevention… 2024 GINA Report — Download for Personal Use [Internet]. 2024. Available from:
https://ginasthma.org/2024-report/
4. World Health Organization. Asthma fact sheet [Internet]. 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
5. Peters M. The Th2-high endotype is characterized by the presence of eosinophilic airway inflammation, whereas the Th2-low endotype is usually characterized by neutrophilic or paucigranulocytic airway inflammation. Front Med [Internet]. 2017;4:158. Available from: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2017.00158/full
6. Varrasi C, Scichilone N, Pelaia C, Malizia E, D’Alessandro F, Scarlata S, et al. Mepolizumab treatment in a 9-year-old boy with severe asthma during SARS-CoV-2
infection: A Case Report. J Clin Med [Internet]. 2024;14(9):1063. Available from: https://www.mdpi.com/2075-1729/14/9/1063
7. Global Initiative for Asthma. GINA 2024 Report: What’s new in 2024 [Internet]. 2024. Available from: https://ginasthma.org/2024-report/
8. Al-Zaabi A, Trowell E, O’Shaughnessy B, Adcock IM, Chung KF, Southworth T. Bronchial thermoplasty resulted in heterogeneous heating of the airway wall. Eur Respir J [Internet]. 2022;59(1):2100622. Available from:
https://publications.ersnet.org/content/erj/59/1/2100622
9. American Academy of Allergy, Asthma & Immunology. Currently there are six approved biologics for asthma – omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab [Internet]. Available from: https://www.aaaai.org/tools-for- thepublic/conditions-library/asthma/biologics-for-the management-of-severe-asthma
10. Global Initiative for Asthma. The GINA 2024 guidelines reflect updated criteria for commencing a particular step of therapy, aiming to optimize management and outcomes in pediatric asthma care [Internet]. 2024. Available from: https://pubmed.ncbi.nlm.nih.gov/39051318/
11. National Center for Biotechnology Information. Asthma is a prevalent chronic inflammatory respiratory condition affecting millions of people worldwide [Internet]. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430901/
12. Global Initiative for Asthma. Bronchial asthma is currently defined as “a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role & [Internet]. 2008. Available from: https://publications.ersnet.org/content/erj/33/4/897
13. National Heart, Lung, and Blood Institute. Asthma Care Quick Reference: Diagnosing and Managing Asthma [Internet]. 2011. Available from: https://www.nhlbi.nih.gov/files/docs/guidelines/asthma_qrg.pdf
14. American Lung Association. Black individuals and Indigenous Peoples have the highest current asthma rates compared to other races and ethnicities [Internet]. 2024. Available from: https://www.lung.org/research/trends-in-lung-disease/asthma-trends- brief/current demographics
15. Matusic M. Asthma is best categorized as increases in lymphocytes throughout the bronchial tree. Resp Ther [Internet]. 2018. Available from: https://respiratory-
therapy.com/disordersdiseases/chronic-pulmonary-disorders/asthma/preventing-airway- remodeling/
16. Matusic M. Treatment upon diagnosis is key when attempting to prevent airway remodeling in patients with bronchial asthma [Internet]. 2018. Available from: https://respiratorytherapy.com/disorders-diseases/chronic-pulmonary- disorders/asthma/preventing-airwayremodeling/
17. Al-Sarayji A, Alkhatib M. Mepolizumab (Anti-IL-5) Indication: Maintenance treatment of severe asthma in patients with an eosinophilic phenotype. Dr Oracle [Internet]. 2024. Available from: https://www.droracle.ai/articles/370085/biologics-for-asthma- andindications-per-current-guidelines-table
18. Global Initiative for Asthma. Stepwise treatment is an approach to adjust pharmacological therapy according to asthma control level. J Asthma Allergy [Internet]. 2023;16:719-731. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10724792/
19. D’Amato F, Vatrella A, Loffredo S, Vitale C, Foggia M, D’Amato M. Diagnostic confusion between COPD and asthma is most likely to arise in older patients with respiratory complaints. Chron Respir Dis [Internet]. 2022;19:1-10. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9683358/
20. Sanofi. Airflow obstruction is often fully reversible in classical asthma, while it is irreversible or partially reversible in COPD [Internet]. Available from: https://pro.campus.sanofi/copd/articles/copd-vs-asthma-learn-the-difference
21. Asthma + Lung UK. What is a bronchial challenge test? [Internet]. Available from: https://www.asthmaandlung.org.uk/symptoms-tests-treatments/tests/bronchial-
challengetests
22. American Lung Association. The challenge test is considered positive if methacholine causes a 20 percent or greater decrease in your breathing ability [Internet]. Available from: https://www.lung.org/lung-health-diseases/lung-procedures-and- tests/methacholinechallenge-test
23. British Medical Journal Best Practice. Differentials [Internet]. Available from: https://bestpractice.bmj.com/topics/en-us/69
24. National Center for Biotechnology Information. Bronchial carcinoid in a 39-year-old man treated for bronchial asthma: A case report [Internet]. 2012. Available from:
https://pmc.ncbi.nlm.nih.gov/articles/PMC3390118/
25. Global Initiative for Asthma. GINA 2024 Stepwise approach for chronic treatment of asthma based on treatment tracks [Internet]. 2023. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10724792/
26. Global Initiative for Asthma. GINA Summary Guide for Asthma Management and Prevention [Internet]. 2024. Available from: https://ginasthma.org/wpcontent/uploads/2024/12/GINA-Summary-Guide-2024-WEB- WMS.pdf

27. Global Initiative for Asthma. For Track 2, the previous descripGion of paGents suitable for Step 1 treatment… has now been replaced, since GINA has recommended against SABA- only treatment since 2019 [Internet]. 2024. Available from: https://ginasthma.org/wpcontent/uploads/2024/06/GINA-Strategy-Report-2024-tracked-
changes-for-archive- WMSA.pdf
28. Global Initiative for Asthma. Add-on maintenance medications: Long-acting muscarinic antagonists (LAMA) and Leukotriene receptor antagonists (LTRA) [Internet]. 2024. Available from: https://ginasthma.org/wp-content/uploads/2024/11/GINA-Severe-Asthma- Guide-2024-WEB-WMS.pdf
29. Pelaia C, Buscaglia S, Vatrella A, Montuori M, Gallelli L. Various conditions such as rhinosinusitis, gastro-oesophageal reflux disease, psychological disturbances, chronic infections and obstructive sleep apnoea are often observed in asthmatic patients. Eur Respir J [Internet]. 2008;33(4):897. Available from: https://publications.ersnet.org/content/erj/33/4/897
30. Price D, Sadatsafavi M. The difficult asthma clinic specialist assessed patient adherence using the components of the validated Adult Asthma Adherence Questionnaire. Eur Respir J [Internet]. 2018;51(4):1701836. Available from: https://publications.ersnet.org/content/erj/51/4/1701836
31. Gómez I. In individuals with severe asthma, comorbidities are common, with the most prevalent being gastroesophageal reflux disease (GERD), sinusitis, allergic rhinitis and nasal polyposis. J Clin Med [Internet]. 2022;15(11):3645. Available from: https://www.elsevier.es/en-revista-clinics-22-articulo-comorbidities-in-severe-asthmafrequency-S1807593222025765
32. Williams D, Kuan M, Bafadhel M, et al. Effective treatment of severe asthma requires patient adherence to inhaled and biological medications. BMJ Open Respir Res [Internet]. 2024;11(1):e001799. Available from: https://bmjopenrespres.bmj.com/content/11/1/e001799
33. Zafari Z, Sadatsafavi M, Marra CA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220-225. Available from: https://publications.ersnet.org/content/erj/51/4/1701836

Ahead of Print Subscription Review Article
Volume 03
02
Received 28/05/2026
Accepted 12/06/2026
Published 27/06/2026
Publication Time 30 Days
1

Login


My IP

PlumX Metrics